FDA premarket notification records identify the Centers for Disease Control and Prevention as the applicant on two recent microbiology submissions, both decided substantially equivalent. The supplied collection contains two linked 510(k) records, both with a SESE decision, and the smaller record sample likewise shows two SESE decisions. These counts describe the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1][2]

Anthrax assay clearance

Submission K262368 covers the B. anthracis Real-time PCR Assay, filed under product code NHT and regulation number 866.3045 in the microbiology specialty. The record lists a receipt date of 2026-07-10 and a decision date of 2026-10-07, with decision code SESE, a Traditional clearance type, no third-party review and a summary statement. The applicant address on the filing is 1600 Clifton Rd., NE, Atlanta, GA. [1]

An earlier anthrax assay filing, K140426, names the same device classification and product code, with a receipt date of 02/19/2014 and a decision date of 05/22/2014, also substantially equivalent and Traditional, not reviewed by a third party. A separate FDA decision summary for K192871 addresses the B. anthracis Real-time PCR Assay under 21 CFR 866.3045, Class II, product code NHT, and notes that the assay may be run on manufacturer-installed and validated software from the AB 7500 Fast Dx, SmartCycler I, SmartCycler II or QuantStudio Dx real-time PCR instruments. [4][5]

Influenza panel scope

Submission K263035 covers the CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, described in the record as including an Influenza A/B Typing Kit, an Influenza A Subtyping Kit, an Influenza A(H5) Subtyping Kit and an Influenza B Lineage Genotyping Kit. It carries product code OZE, regulation number 866.3980 and the microbiology specialty, with a receipt date of 2026-08-31 and a decision date of 2026-09-30. The decision code is SESE, the clearance type is listed as Special, third-party review is marked no, and a summary statement is recorded. [2]

Technology and instrument context

The anthrax assay documentation describes nucleic acid amplification testing for Bacillus anthracis, with master mix components listed as Quanta PerfeCTa MultiPlex qPCR SuperMix, Low ROX and Roche LightCycler FastStart DNA Master HybProbe. The same decision summary directs inquiries about clinical performance characteristics of the B. anthracis Real-time PCR Assay to the Centers for Disease Control and Prevention. A separate FDA summary for the Applied Biosystems Bacillus anthracis Detection Kit, K183462, describes detection of nucleic acid sequences of B. anthracis pX01 and pX02 plasmids on the AB 7500 Fast Dx instrument; that kit is a different applicant's device and is not a CDC filing. [4][6]

CDC's own Emerging Infectious Diseases journal published a 2002 letter titled Evaluation and Validation of a Real-Time Polymerase Chain Reaction Assay for Rapid Identification of Bacillus anthracis, and CDC maintains a laboratory information page for anthrax testing dated Feb. 10, 2026, attributed to the National Center for Emerging and Zoonotic Infectious Diseases and the Division of High-Consequence Pathogens and Pathology. These pages are published by CDC and do not establish commercial availability, customers or performance results for the cleared assays. [7][8]

Applicant identity

Across the supplied filings, the applicant is recorded as Centers for Disease Control and Prevention at a Clifton Road address in Atlanta, Georgia. FDA filing addresses are not treated here as a verified headquarters, and no parent, brand or ownership relationship is documented in these sources. The FDA 510(k) database page for K262368 shows a page update of 10/26/2026 and a Predetermined Change Control Plan Authorized field marked Yes; the corresponding field for K140426 is marked No. [1][3][5]